Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation.

Angiostatin, a circulating inhibitor of angiogenesis, was identified by its ability to maintain dormancy of established metastases in vivo. In vitro, angiostatin inhibits endothelial cell migration, proliferation, and tube formation, and induces apoptosis in a cell type-specific manner. We have used a construct encoding the kringle domains 1--4 of angiostatin to screen a placenta yeast two-hybrid cDNA library for angiostatin-binding peptides. Here we report the identification of angiomotin, a novel protein that mediates angiostatin inhibition of migration and tube formation of endothelial cells. In vivo, angiomotin is expressed in the endothelial cells of capillaries as well as larger vessels of the human placenta. Upon expression of angiomotin in HeLa cells, angiomotin bound and internalized fluorescein-labeled angiostatin. Transfected angiomotin as well as endogenous angiomotin protein were localized to the leading edge of migrating endothelial cells. Expression of angiomotin in endothelial cells resulted in increased cell migration, suggesting a stimulatory role of angiomotin in cell motility. However, treatment with angiostatin inhibited migration and tube formation in angiomotin-expressing cells but not in control cells. These findings indicate that angiostatin inhibits cell migration by interfering with angiomotin activity in endothelial cells.

[1]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[2]  A. Norin,et al.  A novel ligand in lymphocyte-mediated cytotoxicity: expression of the beta subunit of H+ transporting ATP synthase on the surface of tumor cell lines , 1994, The Journal of experimental medicine.

[3]  P. Opolon,et al.  Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. A. Thomas,et al.  Molecular cloning. , 1977, Advances in pathobiology.

[5]  O. Volpert,et al.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.

[6]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[7]  I Que,et al.  Endostatin inhibits VEGF‐induced endothelial cell migration and tumor growth independently of zinc binding , 1999, The EMBO journal.

[8]  Marius Sudol,et al.  From Src Homology domains to other signaling modules: proposal of the `protein recognition code' , 1998, Oncogene.

[9]  M. Llinás,et al.  Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[11]  V. Sukhatme,et al.  Endostatin Induces Endothelial Cell Apoptosis* , 1999, The Journal of Biological Chemistry.

[12]  N. Bouck,et al.  Multiple forms of angiostatin induce apoptosis in endothelial cells. , 1998, Blood.

[13]  D. Rushton,et al.  Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta. , 1995, Growth factors.

[14]  J. Folkman,et al.  Kringle Domains of Human Angiostatin , 1996, The Journal of Biological Chemistry.

[15]  M. Llinás,et al.  Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth* , 1997, The Journal of Biological Chemistry.

[16]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Folkman,et al.  Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Bussolati,et al.  Angiopoietin-1 and angiopoietin-2 activate trophoblast Tie-2 to promote growth and migration during placental development. , 2000, The American journal of pathology.

[19]  D. Hanahan,et al.  Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[21]  K. Hajjar,et al.  Interaction of the Fibrinolytic Receptor, Annexin II, with the Endothelial Cell Surface , 1996, The Journal of Biological Chemistry.

[22]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[23]  P. Dell’Era,et al.  Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[24]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[25]  T. L. Moser,et al.  Angiostatin binds ATP synthase on the surface of human endothelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Zetter,et al.  The chemotactic response to PDGF-BB: evidence of a role for Ras , 1995, Journal of Cell Biology.

[27]  A. Griffioen,et al.  In vitro Tumor Angiogenesis Assays: Plasminogen Lysine Binding Site 1 Inhibits in vitro Tumor-Induced Angiogenesis , 1998, Journal of Vascular Research.

[28]  Jordi Félez,et al.  Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. , 1991, Biochemistry.

[29]  N. Bouck,et al.  How tumors become angiogenic. , 1996, Advances in cancer research.

[30]  C. Kahn,et al.  Analysis of a peptide hormone-receptor interaction in the yeast two-hybrid system. , 1997, Proceedings of the National Academy of Sciences of the United States of America.